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Abstract
Background: Preclinical studies demonstrated that small chain RNA fragments accelerate the recovery of platelets
numbers in animals exposed to high doses of chemotherapeutic drugs. There is anecdotal data supporting the
same application in humans. The Phase I clinical trial described here was designed to investigate the relationship
between the administration of small chain RNA fragments and the recovery in platelets following Chemotherapy-
Induced Thrombocytopenia (CIT).
Methods: Cancer patients with solid tumors that experienced post chemotherapy thrombocytopenia with a nadir
of < = 80,000 platelets/ml were eligible for this clinical trial. There were no exclusions based on ECOG status,
tumor type, tumor burden or chemotherapeutic agents. Patients received a unique preparation of RNA derived
from either E. coli or yeast. Ten patients per group received 20, 40, or 60 mg as a starting dose. Subjects self-
administered RNA fragments sublingually on an every other day schedule while undergoing chemotherapy. The
dose was escalated in 20 mg increments to a maximum dose of 80 mg if the nadir was < 80,000 platelets/ml at
the start of the next cycle. Subjects were treated for three cycles of chemotherapy with the maximum effective
dose of RNA fragments. Subjects continued on planned chemotherapy as indicated by tumor burden without RNA
fragment support after the third cycle. Subjects kept a diary indicating RNA fragment and magnesium
administration, and any experienced side effects.
Results: Patients receiving E. coli RNA fragments demonstrated a more rapid recovery in platelet count and higher
nadir platelet count. None of the patients receiving the E. coli RNA fragments required a chemotherapy dose
reduction due to thrombocytopenia. The optimal dose for minimizing CIT was 80 mg. Conversely, subjects
receiving yeast RNA fragments with dose escalation to 80 mg required a chemotherapy dose reduction per
American Society of Clinical Oncology guidelines for grade 3 and 4 thrombocytopenia.
Conclusions: Patients receiving myelosuppressive chemotherapy experienced an improvement in the platelet nadir
and shorter recovery time when receiving concurrent E coli RNA fragments, when compared to patients who
received yeast RNA fragments. These data indicate that 60 and 80 mg doses of E. coli RNA accelerated platelet
recovery. Further clinical investigations are planned to quantify the clinical benefits of the E. coli RNA at the 80 mg
dose in patients with chemotherapy induced thrombocytopenia.
Trial Registration: Clinical Trials.gov Identifier: NCT01163110
Background
Myelosuppressive chemotherapy has the potential to
produce life threatening neutropenia, anemia, and
thrombocytopenia. All of these conditions compromise
therapeutic dosing which impacts survival as well as
quality of life. The introduction of recombinant growth
factors has enabled oncologists to minimize or prevent
the development of treatment-induced anemia and neu-
tropenia, but the management of chemotherapy-induced
thrombocytopenia (CIT) remains a major challenge.
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lines recommend dose reduction in chemotherapy fol-
lowing onset of thrombocytopenia despite data showing
full dose, on time, chemotherapy leads to reduced
tumor burden and better overall survival [1-3]. Patients
with CIT experience potentially life threatening compli-
cations, delay in treatment, poorer outcomes, and con-
sume inordinate amounts of health care resources for
supportive care [4]. Development of an agent that ame-
liorates CIT would represent a major breakthrough in
cancer treatment.
Platelets are anuclear cell particles that are released
into the bloodstream by megakaryocytes located in the
bone marrow. The differentiation of megakaryocytes is
regulated by an intricate interaction of specific cytokines
and growth factors [5]. Bone marrow stromal elements
are also critical to the differentiation and release of pla-
telets. Cancer chemotherapy often depletes the stem and
progenitor cells involved in platelet proliferation, which
leads to a diminution of platelets and temporary inter-
ruption of platelet production lasting until stromal ele-
ments and megakaryocytes regenerate.
There are several experimental agents targeted to pre-
vent thrombocytopenia. These investigational agents are
cytokines involved in the differentiation and production
of platelets [6]. Currently, the only agent commercially
available for prevention of thrombocytopenia is
Neumega, a derivative of IL-11. Data on Neumega (Opre-
lekin) indicates a shorter duration of chemotherapy-
induced thrombocytopenia, but the toxicity profile has
prevented its widespread introduction into the clinical
setting. Overall, the absence of agents that minimize or
reverse CIT continues to severely limit many patients’
ability to complete the full schedule of chemotherapy at
the doses originally prescribed by treating oncologists [1].
This study is a dose escalation trial investigating the
anti-thrombocytopenic benefits and safety of single
stranded RNA fragments. The short chain RNA frag-
ments are obtained by controlled degradation of prokar-
yotic RNA with ribonuclease. Beljanski showed that
these RNA fragments act as primers for DNA synthesis
in vitro and found that variations in the method of
degradation yielded different preparations that prime
DNA synthesis with distinct tissue specificity. The RNA
fragments used in this study, when administered orally,
localize in the bone marrow where they appear to prime
DNA replication in stem cells resulting in proliferation
of white blood cells and platelets. Beljanski et al.
reported that these specific RNA fragments were effec-
tive in restoring normal levels of circulating platelets
following drug induced thrombocytopenia [7,8]. Demon-
strating the utility of these specific RNA fragments for
prevention and treatment of thrombocytopenia among
cancer patients undergoing chemotherapy is especially
attractive given the absence of the side effects associated
with growth factors and hormones.
This trial investigated the efficacy of two RNA prepara-
tions–extracted, purified and fragmented according
Beljanski’s procedure–to ameliorate CIT: one derived
from E. coli and the second from yeast (a eukaryote).
RNA molecules are present in any diet and can be con-
sidered conditional essential nutrients under conditions
of physiological stress [9]. Purified RNA prepared by var-
ious methods can be found in nutritional products for
hospitalized patients and infant formula [9-11]. This clin-
ical trial evaluated the biologic effects of various doses of
these specially prepared ‘primer’ RNA fragments on pla-
telet numbers in cancer patients who have already devel-
oped thrombocytopenia while undergoing chemotherapy.
Methods
Patient Selection
This is an onsite study conducted at Cancer Treatment
Centers of America® at Midwestern Regional Medical
Center, Zion Illinois, USA. Cancer patients with a solid
tumor, between the ages of 18 and 80 with CIT with
nadir equal to or less than 80,000/ml were eligible to
participate in this study. There was no ineligibility based
on tumor type, tumor burden, prior treatment history,
or chemotherapeutic agents. There were no ECOG per-
formance status restrictions in this investigation, but
patients had to have the physiological capacity to
undergo myelosuppressive chemotherapy and reliability
of self-administration of RNA fragments. After determi-
nation of patient eligibility, subjects signed an Informed
Consent indicating awareness of the investigational nat-
ure of the study and agreement to participate in the first
systematic investigation of this agent. Exclusion criteria
included a life expectancy of less than three months, a
known hypersensitivity to RNA or its metabolic pro-
ducts, or a requirement for administration of therapeutic
heparin (manufacturer’s recommendations).
Experimental Agent
The two test agents are mixtures of single-stranded
chains of 10 to 80 ribonucleotides in length. Both mix-
tures have an overall ratio of purine bases to pyrimidine
bases (G+A)/(C+U) ranging from 1 to 2.5. One test
agent is manufactured by extracting RNA from E. coli
strain K 12, while the other test agent is extracted from
a yeast strain. Both strains are FDA approved for human
consumption. The final product is a lyophilized fraction
with mannitol added to give the powder a sweet taste.
Both RNA extracts is contained in a unit dose vial as a
powder. By manufacturer’s recommendation, patients
self-administered the agents sublingually in combination
with a magnesium supplement every other day to sup-
press the activity of RNA ribonuclease.
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The Institutional Review Board at Cancer Treatment
Centers of America® at Midwestern Regional Medical
Center (MRMC) reviewed and approved the study pro-
tocol in March 2004. After determining eligibility, all
patients gave written informed consent before partici-
pating in the trial. Due to the myelosuppressive poten-
tial of the chemotherapeutic agents, patients were
prophylactically treated with colony stimulating agents
to maintain white and red blood cell production as per
current standards of care [3]. This study was done
sequentially; patient recruitment was completed for the
E. coli arm before the first patient was recruited for the
yeast arm. Each dose was tested in blocks of ten patients
starting with 20 mg. As each block was completed the
dose was escalated to 40 mg, than to 60 mg. All doses
were taken with a magnesium supplement. The magne-
sium supplement slows the rate of degradation of the
RNA fragments in the plasma.
Patient instructions included taking nothing by mouth
for 15 minutes pre and post sublingual administration.
To prevent digestion of the RNA fragments, sublingual
route was chosen. Patients maintained a diary indicating
date and time of RNA fragment administration and com-
pliance of magnesium administration. In order to track
toxicity, patients documented side effects. Weekly blood
counts were evaluated or as needed to evaluate and man-
age the patients risk of bleeding and patients were trans-
fused per ASCO guidelines [9]. These guidelines indicate
that platelet transfusions are required when the patient is
bleeding or their platelet levels have fallen below 20000
cells/ml. We used the Common Toxicity Criteria for
Thrombocytopenia–Grade 0 is normal; Grade 1 <
150000/ml to 75000; Grade 2 i > 50000 < 75000: Grade 3
> 10000 to < 50000: and Grade 4 is < 10000.
Patients red blood counts were measured before the
administration of RNA fragments. To maintain the bio-
logical activity of the RNA fragments, patients had
blood transfusions whenever their red blood cell level
fell below 3 × 10
6 cells/ml.
The initial dose of RNA fragments was 20 mg every
other day at the patient’s convenience. Failure to
respond was defined as platelet nadir of 80,000/ml or
less or a nadir platelet count lower than prior cycle.
Patients that did not achieve platelet levels of greater
then 80,000/ml received a dose escalation in 20 mg
increments until a dose of 80 mg was reached. Conse-
quently, there were more than ten patients in the 40,
60, and 80 mg doses. Subjects were treated for three
cycles of chemotherapy with the maximum effective
dose of RNA fragments. Subjects continued on planned
chemotherapy as indicated by tumor burden without
RNA fragment support after the third cycle.
Outcome Measures
The objective of this trial was two fold. The first goal is
to evaluate the effect of increasing dose of RNA frag-
ments on platelet nadir following chemotherapy and on
platelet recovery time. Secondary outcomes were mea-
s u r e db yo nt i m ec h e m o t h e r a p ya d m i n i s t r a t i o na n dt h e
occurrence of platelet/blood transfusions.
Statistical Methods
Data was collected from patients’ diary and medical
records for analysis. Descriptive statistical analysis of
medians and ranges were performed using the JMP Soft-
ware Package (SAS, Cary, North Carolina). The Kruskal-
Wallis one-way analysis of variance (ANOVA) by ranks,
a non-parametric equivalent of one-way ANOVA, was
used to determine if there was any statistically signifi-
cant difference in nadirs or recovery levels by the dose
level of the RNA fragments.
Results
Patient Characteristics
E. coli RNA Arm
Thirty-two patients signed an informed consent form to
participate in the E. coli RNA fragment trial. Table 1
describes the baseline demographic and clinical charac-
teristics of the patients in greater detail. The median
time between diagnosis of cancer and participation in
this trial was 71 weeks (20 to 347 weeks). Four patients
had no prior history of anti-cancer chemotherapy before
enrollment, but twenty four patients had failed between
one to nine prior regimens (mean 2.5 for all patients).
Furthermore, these patients were exposed to CIT indu-
cing agents, such as, Carboplatin (n = 9), Adriamycin
(n = 10), Cyclophosphamide (N = 9), Cisplatin (n = 6),
and Docetoxel (N = 8). Eight patients were treated with
mitomycin, which can induce persistent bone marrow
damage [12]. Eleven patients had no radiological or clin-
ical signs of metastatic disease, but eleven had meta-
static disease to the bone marrow and six of these had
disease in flat bones, which could affect platelet produc-
tion [12], see table 1. Overall, this patient population
was heavily pretreated with CIT inducing agents and a
significant fraction of these patients experienced Grade
3 CIT (45.7% or 27/59 treatment cycles) at the che-
motherapy induced nadir prior to baseline or at dose
escalation of the RNA fragments (Table 2).
Yeast RNA Fragment Arm
Following the completion of the E. coli trial, forty
patients signed consent forms to participate in the yeast
RNA fragment arm. Nine consented patients did not
participate in the trial; patients dropped out due to dis-
ease progression that required a change in treatment
regimen after signing the consent form or they had
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no history of anti cancer therapy and only two patients
had undergone five or more chemotherapy regimens.
The treated patients were exposed to CIT agents such
as, taxotere (N = 9), carboplatin (N = 9), cisplatin (N =
6), taxol (N = 6); and four patients had prior exposure
to mitomycin. The median time between diagnosis of
disease and participation in the trial was 39 weeks (0 to
296 weeks). All but two patients had metastatic disease.
Eight patients had metastatic disease to the bone and
two of these patients had metastatic disease to the flat
bones that could affect the production of platelets
(Table 1). The prevalence of Grade 3 or Grade 4 throm-
bocytopenia at the nadir prior to baseline or dose esca-
lation of the RNA fragments was 43% (20/46 treatment
cycles) and 4.3% (2/46) respectively (Table 2).
Dose Response Relationships between Chemoprotectant
Dose and Platelet Responses
E. coli RNA Fragment Arm
These patients underwent treatment protocols that con-
tained one or more myelosuppressive agents. The
most common myelosuppressive agents were carboplatin
(n = 11), cisplatin (N = 6), Docetaxel (N = 6), Mitomycin
(N = 5) and premetrexed (N = 5). All but nine patients
used regiments that had multiple CIT inducing agents.
This clinically heterogeneous group of patients likely
had a wide distribution in bone marrow reserve. Conse-
quently, we examined whether there were any differ-
ences in the distribution of platelet counts at the time
of first administration of RNA fragments or at dose
escalation of the RNA fragments at day 1 of chemother-
apy. There was no statistically significant difference in
the platelet count by E. coli RNA fragment dose. The
platelet levels one day 1 of chemotherapy were 162000/
ml (treatment cycle number = 12), 177,500/ml (treat-
ment cycle N = 25), 160000/ml (treatment cycle N =
21), and 187,000/ml (treatment cycle N = 47) for 20 mg,
40 mg, 60 mg and 80 mg respectively (Kruskal-Wallis
P = 0.086). All of the patients on E. coli RNA fragments
showed an oscillation in platelet counts where the plate-
let levels declined after the administration of che-
motherapy and recovered during the rest phase of the
treatment cycle, Figure 1. There was no statistically sig-
nificant difference in the median time to chemotherapy
induced platelet nadirs by RNA fragment dose (Kruskal-
Wallis P = 0. 841). There was no statistically significant
difference in the platelet counts in chemotherapy
induced nadirs by fragment dose, or in the prevalence of
nadir levels less than 25000/ml, which was 16.6%, 21%,
10%, and 24% for 20, 40, 60, and 80 mg levels respec-
tively. The prevalence rate for nadir levels greater than
80000/ml, was 8.3%, 33%, 20%, and 28%, respectively for
20, 40, 60, and 80 mg indicating the relative failure of
the 20 mg dose. This trend was a statistically significant
(p < .05). Finally, there was a statistically significant
shortening in time from chemotherapy induced nadir to
attaining recovery platelet level of 80000/ml or
more from a median recovery time of eight days for the
Table 1 Baseline Characteristics of Patients
Characteristic E. coli (N = 32) Yeast (N = 31)
Age
Median 52 55.7
Range 35 to 70 29 to 73
Sex
Male 9 12
Female 23 19
Prior chemotherapy
none 4 9
16 1 3
27 8
35
42
>5 7 1
Tumor Type
Pancreas 7 4
Breast 10 5
Colon 7 6
Esophageal 4 1
Other 1 6
Lung 3 9
Bone Metastasis
No 21 23
Yes 5 6
Yes, disease in flat bones 6 2
Metastatic Disease
No 11 4
One site 12 13
Multiple sites 9 14
Prior use of Mitomycin 8 5
Table 2 Distribution of Grade of Thrombocytopenia by
Source and Dose of RNA Fragments
E. coli RNA fragments
Grade/Dose 20 mg 40 mg 60 mg 80 mg
11 1 2
23 7 1 2 6
3 6948
4 0000
Yeast RNA fragment
Grade/Dose 20 mg 40 mg 60 mg 80 mg
1 1323
2 4263
3 3548
4 1100
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for the other doses (Kruskal-Wallis P = 0.044).
Finally, there were several patients who exhibited slo-
wed rates of platelet recovery following removal of the
E. coli RNA fragments.
Yeast RNA fragment Arm
All but seven patients underwent regimens that used
multiple CIT inducting agents. The most common CIT
agents used in the regimens were Carboplatin (N = 7),
cisplatin (N = 7), and mitomycin (N = 7). Patients parti-
cipating in the yeast RNA trial were a clinically hetero-
geneous group. We evaluated whether there were any
differences in the distribution of platelet counts at the
time of first administration of RNA fragments or at
dose escalation of the yeast RNA fragments at day 1 of
chemotherapy. The median platelet levels on che-
motherapy day 1 were 124,500/ml (treatment cycle N =
11), 157000/ml (treatment cycle N = 18), 143000/ml
(treatment cycle N = 13), and 128500/ml (treatment
cycle N = 31) for 20, 40, 60, and 80 mg respectively
(Kruskal-Wallis p = 0.334).
There was no statistically significant difference in the
time to chemotherapy induced platelet nadir by RNA
fragment dose level (Kruskal-Wallis P = 0.824) nor a
statistically significant relationship in the platelet nadir
counts by RNA dose; the median nadir levels were
42000/ml, 66000/ml, 45000/ml, and 53000/ml for 20,
40, 60, and 80 mg dose levels respectively. Unlike the
E. coli data, there was no statistically significant shorten-
ing in the time from chemotherapy induced nadir to a
recovery platelet level of 80000; median platelet recovery
times were 12, 7, 12, and 11.5 days for 20, 40, 60, and
80 mg doses (Kruskal-Wallis P = 0.573).
Unlike the patients on E. coli fragments, seven
patients using yeast RNA fragments failed to demon-
strate an oscillation in platelet counts, Figure 2. In
these cases platelet levels declined after the administra-
tion of chemotherapy but either did not recover or
recovered very slowly during the rest phase of the
treatment cycle.
Dose Response Relationships
The dose response relationships with E. coli RNA frag-
ments chemotherapy induced platelet nadir levels were
evaluated at baseline or the initial dose escalation of
RNA fragments. The median nadir platelet levels ranged
from 46000 at 20 mg to 55000 for the 80 mg, which
was not statistically significant (Kruskal-Walis two sided
p = 0.581). As administered in this study, increasing the
dose of E. coli RNA fragments do not affect chemother-
apy’s capacity to depress platelet levels. Similarly, there
was no statistically significant dose response relationship
between nadir levels and increasing doses of yeast RNA
fragments (Kruskal-Walis P = 0.262).
There was a significant relationship between recovery
platelet levels and increasing doses of E. coli RNA frag-
ments at the baseline or initial dose escalation of RNA
fragments. Platelet recovery levels were measured
between five to eight days following chemotherapy
induced nadirs. The median recovery platelet counts
rose from 110000/ml at 20 mg to 130000/ml at 60 mg
and 149000/ml at 80 mg (Kruskal-Wallis two sided p =
0.0149). There was no observed relationship between
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platelets five to eight days post chemotherapy induced
nadir (Kruskal-Wallis P = 0.31). There was a statistically
significant difference in Platelet recovery levels by type
o fR N Af r a g m e n t s .E .c o l iF r a g m e n t sa tt h e6 0a n d8 0
mg levels exhibited a statistically significant higher
recovery level five to eight days after chemotherapy
induced nadir than Yeast RNA fragments (Kruskal-
Wallis P < 0.001, Figure 3).
There were twelve patients who were treated with
60 mg of E coli RNA fragments that were dose escalated
to the 80 mg dose. We, therefore, compared the efficacy
of the 80 mg dose to the 60 mg dose on the patients’
nadir levels. The platelet counts at the 60 mg dose ran-
ged from 17000 to 72000 (median 45500) in these
twelve patients, while their nadir platelet counts follow-
ing dose escalation to 80 mg dose of E coli RNA frag-
ments ranged by 16000 to 129000 (median 65,500). A
pair-wise comparison found that nine patients had
higher nadirs at the dose escalated 80 mg dose (platelet
counts increased by 17,000 to 109,000) compared to
their nadirs at 60 mg, three patients had lower platelet
counts following dose escalation to 80 mg dose (platelet
counts decreased from 7,000 to 30000). Overall, there
was a statistically significant difference between these
two groups (Wilcoxon Signed Test P = 0.011).
Stratification by Chemotherapy
All of the patients recruited to this trial had the poten-
tial to develop clinically concerning chemotherapy
induced low platelet levels. Among the wide variety of
chemotherapeutic agents used in this trial, Platinum
based agents and Mitomycin were the most efficient
inducers of CIT. In both E. coli RNA and Yeast RNA,
there was no statistically significant difference in the
platelet number five to eight days after chemotherapy
induced nadir between treatment protocols that used
platinum based agents or mitomycin and those that did
not, see table 3 and 4.
Clinical Sequelae and Platelet Support
The primary clinical goal of anti-chemotherapy induced
thrombocytopenia is the avoidance of delays in treat-
ment and reductions in the dose of chemotherapy. Four
patients experienced a treatment delay or reduction in
chemotherapy dose in the yeast fragment arm of the
trial, but no patient using E. coli, RNA fragments had
an unplanned dose reduction or delay.
The other important clinical goal for anti thrombocy-
topenia is the reduction and prevention of platelet trans-
fusions. Four patients had platelet transfusions while
taking E. coli RNA. At the 20 mg dose two patients had
platelet transfusions. One of these patients had a con-
current GI bleed related to tumor. At the 40 mg level,
two patients had platelet transfusions and one experi-
enced a cerebral bleed. There were no platelet transfu-
sions in patients dosed at the 60 or 80 mg E coli, RNA
fragments.
Three patients required platelets when they came off
trial or failed to use E. coli fragments. Two patients had
platelet transfusions 30 days and 16 days after coming
off E. coli RNA fragment trial while the third experi-
enced bleeding gums and required one unit of platelets
after inadvertently failing to take RNA fragments for
one treatment cycle. Interestingly, this patient under-
went multiple cycles of Myelosuppressive Therapy with
E. coli RNA fragments before and after this unprotected
cycle without incident. These data are consistent with
the hypothesis that E coli RNA fragments accelerate the
recovery in platelet counts following chemotherapy-
induced thrombocytopenia.
Four of the thirty-one patients on the yeast RNA arm
of the trial had platelet transfusions; one transfusion at
4 0m g ,t h r e ea t6 0m g ,a n do n ea t8 0m gd o s e s .N o
thrombocytopenic related symptoms were reported
among these patients.
Discussion and Conclusions
The emergence of Grade 3 or 4 thrombocytopenia in a
cancer patient correlates with a significant worsening in
the patient’s prognosis [3]. Among the other agents in
development for treatment of CIT the mechanism of
action of short chain prokaryotic RNA fragments is
unique. Both cell division and differentiation are
required for platelet proliferation, and DNA replication
60 mg yeast 60 mg e coli 80 mg yeast 80 mg e coli
Comparison in Platelet Recovery Levels following 
CIP Nadirs by Type of RNA Fragments
Dose of RNA Fragments
R
e
c
o
v
e
r
y
 
P
l
a
t
e
l
e
t
 
N
u
m
b
e
r
 
0
50
100
150
200
250
Figure 3 Comparison in Platelet Recovery Levels following CIP
Nadirs by Type of RNA Fragments.
Levin et al. BMC Cancer 2010, 10:565
http://www.biomedcentral.com/1471-2407/10/565
Page 6 of 8is the primary step. DNA synthesis depends on special
naturally produced short chain RNA fragments as pri-
mers for DNA polymerase [13-15]. These natural pri-
mers might very well derive from the RNA of intestinal
E. coli absorbed fragmented by native RNAases. In che-
motherapy patients, in whom damage to cells of the
intestinal lining is a common side effect, the E. coli
RNA fragments developed by Beljanski appear to fulfill
this primer function when administered exogenously.
In vitro studies show that these RNA fragments act as
primers for DNA synthesis in the progenitor cells that
give rise to platelets [5,6].
By study criteria, all trial participants had developed
grade 1, 2, or 3 CIT before being administered the study
drug. Moreover, all of these patients had experienced
e x t e n s i v ep r i o rh i s t o r yo fe xposure to myelosuppressive
drugs and approximately a third of these patients had
metastatic disease to the bone marrow where platelets
are produced thereby identifying them to be at high risk
for Grade 3 or 4 CIT.
At all doses, patients receiving E. coli RNA fragments
showed a recovery in platelet numbers to 80000/ml by
eight days following chemotherapy induced nadir. More-
over, the platelet recovery levels following chemotherapy
induced nadir rose in a dose dependant manner from
110000 at the 20 mg dose to 149000 at the 80 mg dose.
No patient had an unplanned dose reduction or treat-
ment delay nor did any E. coli RNA fragment patient
treated at the 60 and 80 mg dose level need a platelet
transfusion although four patients had platelet
transfusions at the lower doses. After discontinuing
E. coli RNA fragment therapy, there appeared to be a
decline in the recovery rate of platelet numbers in five
patients, which suggest the RNA fragments were
involved in accelerating platelet recovery in these
patients.
Seven patients using yeast RNA fragments failed to
show a rebound in platelets numbers following che-
motherapy induced nadir. Four yeast RNA fragment
patients experienced dose reductions or delays in their
treatment. There was no evidence of a dose response
relationship between yeast RNA and platelet recovery
levels following chemotherapy induced nadirs and there
were platelet transfusions at the higher three yeast RNA
dose levels (40, 60, and 80 mg). There was no relation-
ship found between the specific chemotherapy agents
and platelet recovery levels. These data indicate that
RNA fragments manufactured from yeast are less effec-
tive than RNA fragments manufactured from E. coli in
accelerating the rate of platelet recovery following CIT.
Limitations of this trial include inconsistent timing
and frequency of platelet counts. Prospectively collected
data on patients provided outcomes regarding adminis-
tration of agent and side effects but did not include the
signs and symptoms of thrombocytopenia such as bleed-
ing or petechiae. There was a lack of consistency of doc-
umentation in the patient diary and not all diaries were
presented to the data management team. All efforts
were made to capture missing data from the medical
record and personal contact with patient. This was also
Table 3 The Relationship between Therapeutic Agents and Platelet Recovery Following Nadir in E. coli
RNA Fragments Dose Chemotherapy Patient Number Median Platelet Counts Range Kruskall Wallis
E. coli 60 Non mito, non Platinum 11 163 90 to 257 0.09
Carboplatin 2 122.5 118 to 127
Cisplatin 2 95 62 to 129
Mitomycin C 1 62 62
E. coli 80 Non mito, non Platinum 10 137.5 83 to 210 0.3
Carboplatin 2 156 110 to 202
Cisplatin 1 173 173
Mitomycin C 2 168 149 to 187
Table 4 The Relationship between Therapeutic Agents and Platelet Recovery Following Nadir in Yeast
RNA Fragments Dose Chemotherapy Patient Number Median Platelet Counts Range Kruskall Wallis
Yeast 60 Non mito, non Platinum 5 21-235
Carboplatin 4 56-130
Cisplatin 2 101-206
Mitomycin C 1 101
Yeast 80 Non mito, non Platinum 6 57-244
Carboplatin 7 33-121
Cisplatin 1 185
Mitomycin C 3 40-90
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an anti-thrombocytopenia drug. A significant fraction of
these patients had already failed one or more regimens,
some had used agents that induce long term bone mar-
row damage while others had metastatic disease to the
bone. Many patients in this trial experienced tumor pro-
gression which resulted in their being terminating from
the trial. In this challenging patient population, we
found data that a 80 mg dose of E coli RNA fragments
appear to accelerate platelet recovery in patients under-
going chemotherapy and we have data suggesting the
80 mg E coli RNA may ameliorate chemotherapy
induced thrombocytopenia. This preliminary data sup-
ports the development of further clinical trials designed
to measure the efficacy of E. coli RNA fragments in the
management of CIT among patients with advanced
cancer.
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